VTRS Key Statistics, Chart & Performance
The current stock price of VTRS is 12.37 USD. In the past month the price increased by 15.72%. In the past year, price increased by 0.73%.
VTRS Latest News, Press Relases and Analysis
VTRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.06 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.07B | ||
| MRK | MERCK & CO. INC. | 12.1 | 264.63B | ||
| PFE | PFIZER INC | 7.81 | 142.14B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.25 | 110.15B | ||
| ZTS | ZOETIS INC | 19.87 | 55.52B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.51 | 22.56B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.59 | 11.25B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.7 | 8.40B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.60B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.77B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.51B |
Related stock screener links
About VTRS
Company Profile
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
Company Info
VIATRIS INC
1000 Mylan Boulevard
Canonsburg PENNSYLVANIA 15317 US
CEO: Michael Goettler
Employees: 32000
Phone: 17245141465
VIATRIS INC / VTRS FAQ
What does VIATRIS INC do?
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
Can you provide the latest stock price for VIATRIS INC?
The current stock price of VTRS is 12.37 USD. The price increased by 0.41% in the last trading session.
Does VTRS stock pay dividends?
VIATRIS INC (VTRS) has a dividend yield of 3.92%. The yearly dividend amount is currently 0.48.
What is the ChartMill technical and fundamental rating of VTRS stock?
VTRS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
When is the next dividend date for VIATRIS INC (VTRS)?
The next ex-dividend date for VIATRIS INC (VTRS) is November 24, 2025.
Should I buy VTRS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTRS.
Can you provide the growth outlook for VIATRIS INC?
The Revenue of VIATRIS INC (VTRS) is expected to decline by -4.73% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
VTRS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VTRS. When comparing the yearly performance of all stocks, VTRS is one of the better performing stocks in the market, outperforming 74.91% of all stocks.
VTRS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to VTRS. There are concerns on the financial health of VTRS while its profitability can be described as average.
VTRS Financial Highlights
Over the last trailing twelve months VTRS reported a non-GAAP Earnings per Share(EPS) of 2.33. The EPS decreased by -14.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.73% | ||
| ROE | -24.26% | ||
| Debt/Equity | 0.82 |
VTRS Forecast & Estimates
17 analysts have analysed VTRS and the average price target is 12.71 USD. This implies a price increase of 2.71% is expected in the next year compared to the current price of 12.37.
For the next year, analysts expect an EPS growth of -10.8% and a revenue growth -4.73% for VTRS